Dublin Core
Title
Treatments for Squamous Cell Cancer
Subject
Cancer
Description
Squamous cell cancer (SCC) development and recent preclinical and clinical advances for the effective prevention and treatment of the disease are covered in this book. Experts in the field describe here the cellular and molecular events in SCC development, recurrence, and metastasis, and provide an updated snapshot on our understanding of the heterogeneity of SCC pathogenesis with novel opportunities in precision therapeutics to achieve better clinical outcomes.
URI
https://directory.doabooks.org/handle/20.500.12854/97412
Keywords
n/a; oral cancer; tobacco; alcohol; human papilloma virus; targeted sequencing; DNA copy number; TP53; CDKN2A; EGFR; PIK3CA; anal cancer; radiation therapy; chemoradiation; de-escalation of therapy; pain; cathepsin S; protease-activated receptor-2; PAR2; cancer pain; oral squamous cell carcinoma; differentiation; terminal differentiation; oral epithelium; epithelial integrity; epithelial transformation; genetic alterations; therapy response biomarkers; cutaneous squamous cell carcinoma; immunotherapy; anti-PD1; biomarkers; predictive medicine; personalized medicine; cancer; immune system; HNSCC; farnesyl transferase; tipifarnib; combination regimen; oropharynx; neoplasm; squamous cell carcinoma; human papillomavirus; therapeutic management; treatment selection; CSCC; treatment; advances; biology; immunocompromised; immune checkpoint inhibition
URI
https://directory.doabooks.org/handle/20.500.12854/97412
Keywords
n/a; oral cancer; tobacco; alcohol; human papilloma virus; targeted sequencing; DNA copy number; TP53; CDKN2A; EGFR; PIK3CA; anal cancer; radiation therapy; chemoradiation; de-escalation of therapy; pain; cathepsin S; protease-activated receptor-2; PAR2; cancer pain; oral squamous cell carcinoma; differentiation; terminal differentiation; oral epithelium; epithelial integrity; epithelial transformation; genetic alterations; therapy response biomarkers; cutaneous squamous cell carcinoma; immunotherapy; anti-PD1; biomarkers; predictive medicine; personalized medicine; cancer; immune system; HNSCC; farnesyl transferase; tipifarnib; combination regimen; oropharynx; neoplasm; squamous cell carcinoma; human papillomavirus; therapeutic management; treatment selection; CSCC; treatment; advances; biology; immunocompromised; immune checkpoint inhibition
Creator
Darido, Charbel (editor)
Source
https://directory.doabooks.org/handle/20.500.12854/97412
Publisher
MDPI - Multidisciplinary Digital Publishing Institute
Date
2022
Contributor
Dewi Puspitasari
Rights
https://creativecommons.org/licenses/by/4.0/
Relation
Campbell, J.D.; Yau, C.; Bowlby, R.; Liu, Y.; Brennan, K.; Fan, H.; Taylor, A.M.;Wang, C.;Walter, V.; Akbani, R.; et al. Genomic,
Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018, 23, 194–212.e196. [CrossRef]
[PubMed]
Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018, 23, 194–212.e196. [CrossRef]
[PubMed]
Format
Pdf
Language
English
Type
Textbooks
Identifier
DOI
10.3390/books978-3-0365-4757-2
10.3390/books978-3-0365-4757-2
ISBN
9783036547589, 9783036547572
9783036547589, 9783036547572
Coverage
Basel